Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA in PTSD
NCT03752918Phase 1Withdrawn
- Sponsor
- Yale University
- Start
- May 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of midomafetamine in post-traumatic stress disorder (PTSD) (2 arms), sponsored by Yale University. Primary endpoint: Changes in activation of mPFC, amygdala, and nucleus accumbens upon presentation of emotional faces. Planned start May 2024; status: withdrawn.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT03752918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03752918.